Source - LSE Regulatory
RNS Number : 9189X GSK PLC 20 February 2025 GSK plc (the 'Company') Vesting of Performance Share Plan Awards This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2022 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards were made in 2022 and the three-year performance period commenced on 1 January 2022 and ended on 31 December 2024. The vested shares for the Executive Directors are now subject to an additional two-year vesting period. The performance measure vesting details for those PDMRs who received awards in 2022 are set out in the following table. Outcome and Vesting Level Portion of the Award Measure and Outcome % of maximum % of award 30% Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 5th, against a comparator group of 10 global pharmaceutical companies including GSK. 40% 12% 20% Total Sales - For the three-year period, the Company achieved sales across our marketed products for the measure of £86.15bn, which is above the level of £80.29bn required for 100% vesting. The threshold vesting level was £75.71bn. 100% 20% 20% Total Profit - For the three-year period, the Company achieved £24.2bn, which is above the level of £23.62bn required for 100% vesting. The threshold vesting level was £22.27bn. 100% 20% 20% Pipeline Progress - measure is equally weighted between: - Pivotal trial starts - Major regulatory approvals 100% 87.5% 10% 8.75% 10% Trust: Environment - For the three-year period, all criteria for achieving our Trust priority and goal of having a Nature Net Positive and Climate Net Zero impact by 2030 have been met or exceeded in advance of the target date required to result in maximum vesting for this measure. 100% 10% Total vesting for 2022 award Lapsed 80.75 19.25 80.75% The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 18 February 2025. The balance of the award made to each PDMR and PCA has lapsed. The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting date were £14.43 and $36.61. Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan. These shares are now subject to a two-year hold. c) Price(s) and volume(s) Price(s) Volume(s) £0.00 420,177 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Diana Conrad b) Position/status Chief People Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 88,027 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Diana Conrad b) Position/status Chief People Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 47,121 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name James Ford b) Position/status SVP and Group General Counsel, Legal and Compliance c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 143,381 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name James Ford b) Position/status SVP and Group General Counsel, Legal and Compliance c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 67,390 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Sally Jackson b) Position/status SVP, Global Communications and CEO Office c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 50,221 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Sally Jackson b) Position/status SVP, Global Communications and CEO Office c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 23,604 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Luke Miels b) Position/status Chief Commercial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 208,808 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Luke Miels b) Position/status Chief Commercial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 14,763 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Shobie Ramakrishnan b) Position/status Chief Digital and Technology Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs') ISIN: US37733W2044 b) Nature of the transaction The number of ADSs vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) $0.00 47,681 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Shobie Ramakrishnan b) Position/status Chief Digital and Technology Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs') ISIN: US37733W2044 b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) $36.6355 25,705 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction New York Stock Exchange (XNYS) 1. Details of PDMR/person closely associated with them ('PCA') a) Name David Redfern b) Position/status President, Corporate Development c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 153,657 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name David Redfern b) Position/status President, Corporate Development c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 72,219 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Regis Simard b) Position/status President, Global Supply Chain c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 135,261 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Regis Simard b) Position/status President, Global Supply Chain c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 63,573 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Phil Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 70,869 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Phil Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 33,309 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Deborah Waterhouse b) Position/status CEO, ViiV Healthcare and President, GSK Global Health c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 133,405 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Deborah Waterhouse b) Position/status CEO, ViiV Healthcare and President, GSK Global Health c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 62,701 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Tony Wood b) Position/status Chief Scientific Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 97,444 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Tony Wood b) Position/status Chief Scientific Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 45,799 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Victoria Whyte b) Position/status Company Secretary c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £0.00 10,755 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Victoria Whyte b) Position/status Company Secretary c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2531 5,055 d) Aggregated information N/A (single transaction) Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction London Stock Exchange (XLON) This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHSEDFISEISEEE
